Rutgers Cancer Institute of New Jersey Awarded $1.3M for Cancer Metabolism and Growth Research Program

Rutgers Cancer Institute has received a $1.3 million, five-year grant from the National Cancer Institute to support the Cancer Metabolism and Growth and Tumor Host Interactions Training Program which will provide postdoctoral candidates the highest quality training and research experience.

Read more

Exploring PD-L1 Expression in Malignant Peritoneal Mesothelioma

In a recent study from Rutgers Cancer Institute of New Jersey, researchers tested whether or not mesothelioma cancer cells express high amounts of PD-L1, a protein that is abundantly present on some types of cancer cells. The PD-L1 protein is an inhibitory molecule that binds to the PD-1 receptor on T-cells, which are cells known to have the ability to recognize and destroy cancer cells in the body. Results of the work are being shared as a poster presentation at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care virtual meeting.

Read more

Exploring Amino Acids Signaling as Intervention for Diabetes and Pancreatic Cancers

Researchers from Rutgers Cancer Institute of New Jersey previously identified a small protein called Rab1A that regulates amino acid signaling. In a recent study, researchers explored the physiological role of Rab1A in mammals using mice though a technique in which one of an organism’s genes is made inoperative, known as genetic knockout.

Read more

Exploring Mutational Signatures Associated with Exposure to Carcinogenic Microplastic Compounds

According to the World Health Organization (WHO), plastic products and their chemical derivatives present in the environment present public health concerns, including elevated risk of cancer. Researchers from Rutgers Cancer Institute of New Jersey explored to what extent common components in microplastic pollutants cause DNA damage in human cells.

Read more

Rutgers Cancer Institute of New Jersey Experts Available to Discuss Colorectal Cancer Topics through March

Various specialists from Rutgers Cancer Institute of New Jersey are available for comment on colorectal cancer topics during the month of March to highlight colorectal cancer awareness month.

Read more

Negligible Detection of SARS-CoV2 found in Environmental Surface Testing of Hematology/Oncology Inpatient and Outpatient Settings

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study, published in Cancer, revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.

Read more

Rutgers University Cancer Prevention Researcher and Leader named President-Elect of American Society of Preventative Oncology

Anita Kinney, PhD, director of the Center for Cancer Health Equity at Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, has been elected as the 2021 president-elect of the American Society of Preventative Oncology (ASPO), a multi-disciplinary society that is committed to serving as an advocate for cancer prevention and control research. In this role, she will serve a two-year term prior to serving as president of the society.

Read more

Mason Scientists and Rutgers Cancer Institute of New Jersey Collaboration Receives U.S. Army’s Breakthrough Award to Better Inform HER2 Breast Cancer Treatment

A Rutgers Cancer Institute of New Jersey and George Mason University collaboration received the U.S. Army’s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments.

Read more

Exploring Impact of Surgery Delays for Clinical Renal Cell Carcinoma Patients during the COVID-19 Pandemic

During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.

Read more

Gallbladder and Bile Ducts: Small Organs with Big Responsibilities

Gallbladder cancer and bile duct cancers are rare, which is why it is important to learn the signs and symptoms of these diseases and help spread awareness. Rutgers Cancer Institute expert highlights these types of cancers for Gallbladder and Bile duct cancer awareness month.

Read more

Gynecologic Oncology Leader Named at New Jersey’s Only NCI-designated Comprehensive Cancer Center

Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey’s largest academic medical center.

Read more

Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. This research has been published in the January 2021 online issue of Journal of Clinical Oncology.

Read more

First Patient Recently Treated with New Non-Surgical Therapy for Urothelial Cancer at Rutgers Cancer Institute

Upper tract urothelial cancer (UTUC) is a subset of urothelial cancer that is found in the renal pelvis or the ureter, part of the genitourinary tract. Surgery has remained the mainstay of treatment for this type of cancer, until last year, when the U.S. Food and Drug Administration (FDA) approved mitomycin gel as the first non-surgical therapy option to treat this type of cancer. Rutgers Cancer Institute of New Jersey has recently treated its first UTUC patient with this new therapy.

Read more

Research Leader Named to Rutgers Cancer Institute from National Cancer Institute to Build World-Class Cancer Immunology and Immunotherapy Programs

Research Leader Christian Hinrichs, MD, has been named Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey,

Read more

Rutgers Cancer Institute of New Jersey Receives $25 Million Gift for Cancer Immunology and Metabolism Center of Excellence

A $25 million transformational gift given to Rutgers Cancer Institute will provide critical support for the Cancer Immunology and Metabolism Center of Excellence to help scientists better understand the human immune response to cancer and ultimately develop the foundation for new treatments or make existing therapies more effective.

Read more

Safely Donate Blood This Winter

With the added concern of COVID-19 safety, there will be drop in the donation of critically needed blood throughout the United States, which is typically low during the winter months. Expert from Rutgers Cancer Institute of New Jersey urges giving the gift of life by donating blood.

Read more

More Joy, Less Stress: Coping With Cancer through the Holiday Season

The holiday season can be challenging for those impacted by cancer. This time may be especially demanding and draining, creating mixed emotions and added stress due to the COVID-19 pandemic. Expert from Rutgers Cancer Institute of New Jersey provides some strategies to consider for less stress this holiday season.

Read more

Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients

Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.

Read more

Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma

Older individuals are at an increased risk of developing primary central nervous system lymphoma (PCNSL). In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute of New Jersey and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.

Read more

Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.

Read more

Exploration of Genomic Ancestry in B-Cell Malignancies Identifies Multiple Important Genomic Differences

Investigators from Foundation Medicine, Inc. and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, examined genomic ancestry in BCL subtypes applying genomic ancestry prediction methodology to comprehensive genomic profiling data and found multiple genomic differences. Results of the study will be shared at the virtual American Society of Hematology Annual Meeting.

Read more

Rutgers Cancer Institute of New Jersey to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition

The American Society of Hematology (ASH), is the world’s largest professional society with a focus on the causes and treatment of blood disorders. Experts from Rutgers Cancer Institute of New Jersey will be presenting a variety of key hematology data at the 62nd American Society of Hematology Annual Meeting. This includes 22 scheduled presentations, including 10 oral presentations examining several types of blood cancers including leukemia, lymphoma, and myeloma.

Read more

Exploring the Role of Tumor Suppressor Enhancers in the Development of T-cell Acute Lymphoblastic Leukemia

Researchers from Rutgers Cancer Institute of New Jersey identified a novel enhancer that interacts with a tumor suppressor gene and explored its involvement in normal T-cell development as well as in T-cell acute lymphoblastic leukemia (T-ALL).

Read more

Take Part in the 2020 Great American Smokeout

November 19, 2020 marks the Great American Smokeout, an annual intervention hosted by the American Cancer Society as a call to action to take the first step towards better health through the elimination of tobacco products. Rutgers experts share more on why and how to get started.

Read more

Exploring Autophagy as a Therapeutic Strategy against Frequent Mutations in Non-Small Cell Lung Cancer

Rutgers Cancer Institute of New Jersey expert investigates the role of a cellular survival mechanism known as autophagy in the formation of tumors driven by mutations in tumor suppressors known as LKB1 and oncogene KRAS.

Read more

Studying Patterns of Relapse in Pediatric Hodgkin Lymphoma using a Response-Based Therapy Approach

Recent research from Rutgers Cancer Institute of New Jersey expert as part of a phase 3 study from the Children’s Oncology Group explores response-based consolidation with modern radiation therapy as safe and effective standard of care for pediatric Hodgkin lymphoma patients. This work is being presented at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) this week.

Read more

Rutgers Cancer Institute of New Jersey Awarded $1.6M for Rutgers Youth Enjoy Science (RUYES) Program for Underrepresented Youth and Educators

The Rutgers Youth Enjoy Science (RUYES) program, funded by the National Cancer Institute, will engage underrepresented minority undergraduate and high school students in cutting-edge cancer research, curriculum support, and professional development activities.

Read more

The Future of Breast Cancer Care is Here

Breast cancer care has changed in a myriad of ways thanks to advances in research, targeted therapies, and more personalized approaches to treatment. Rutgers Cancer Institute breast expert shares more about how the future of breast cancer care is here.

Read more

$50K Grant Supports Exploration of Treatment for Liver Cancer

Incidence and mortality of hepatocellular carcinoma (HCC), a common type of liver cancer, is increasing in the United States. Rutgers Cancer Institute of New Jersey experts have received a $50,000 award through the Translational Research Pilot Award Program that will support the examination of how a drug combination impacts the growth of both human HCC cancer cells and tumors in laboratory models, with the goal of identifying a new treatment for patients with this disease.

Read more

Rutgers Cancer Institute Research: Breastfeeding is Safe for Breast Cancer Survivors of Reproductive Age

Is breastfeeding safe and possible for mothers who have a history of breast cancer? Investigators at Rutgers Cancer Institute of New Jersey recently explored this question by conducting a systematic review on the feasibility and challenges of breastfeeding among breast cancer survivors of reproductive age.

Read more

Tackling Breast Cancer with Screening and Prevention

While researchers continue to make advances in breast cancer detection and treatment, one of the best ways to tackle the disease is through early detection and screening. Rutgers Cancer Institute expert shares more about risk factors, warning signs, and screening.

Read more

Thyroid Cancer: Small Gland, Big Impact

The thyroid is a key part of the endocrine system, a small gland at the base of your neck that produces a hormone that helps control your body’s metabolism. One of the most common and treatable cancers in the United States is thyroid cancer. Rutgers Cancer Institute expert discusses research and treatment for this disease.

Read more

What Every Woman Should Know About Preventing Gynecologic Cancers

The best defense against gynecologic cancer starts with preventative measures. When cancer is detected early, there is a better chance of having more effective treatment and better outcomes. While there is not a single screening test for all gynecologic cancers, learn about the ones that do exist.

Read more

What Does it Mean to be An NCI-Designated Comprehensive Cancer Center?

Rutgers Cancer Institute is a National Cancer Institute-designated Comprehensive Cancer Center, a designation reserved for those cancer centers who meet the highest of standards in research, treatment, prevention and education. Rutgers Cancer Institute expert explains why this distinction sets Rutgers Cancer Institute and RWJBarnabas Health apart.

Read more

Surgery Milestone Reached for Rutgers Cancer Institute Urologic Oncology Leader at Robert Wood Johnson University Hospital

Rutgers Cancer Institute of New Jersey Urologic Oncology chief marks a major milestone in completing his 2,000th robotic prostatectomy at Robert Wood Johnson University Hospital, an RWJBarnabas Health facility and one of the few hospitals in the state designated to teach surgeons about this technique.

Read more

Cancer Care Can’t Wait

Further delaying your preventative cancer care may cause more harm than good. Expert from Rutgers Cancer Institute of New Jersey explains how most colorectal cancers can be prevented through regular screenings, and it is safe to get your screenings, even during these difficult times.

Read more